Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 13,471 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endocrine Disorders Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes

NCT04025281
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Extra Virgin Olive Oil, Refined Olive Oil
Other
Lead sponsor
Griffin Hospital
Other
Eligibility
25 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Nov 10, 2026, 7:16 PM EST
Recruiting Phase 4 Interventional

Vasoactive Drugs in Intensive Care Unit

NCT02118467
View directory record Official record
Conditions
Shock
Interventions
Norepinephrine, Epinephrine, Phenylephrine, Vasopressin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 10, 2026, 7:16 PM EST
Terminated Phase 2 Interventional Results available

Celecoxib for Thyroid Eye Disease

NCT02845336
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Celecoxib, artificial tears
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 10, 2026, 7:16 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

NCT06335771
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
Interventions
Dietary consultation weight loss intervention
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 10, 2026, 7:16 PM EST
Terminated Phase 4 Interventional Results available

TOM: Testosterone in Older Men With Sarcopenia

NCT00240981
View directory record Official record
Conditions
Sarcopenia, Hypogonadism, Muscular Diseases
Interventions
Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation)
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
65 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 10, 2026, 7:16 PM EST
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Topical Human FGF-1 for Wound Healing

NCT00916292
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
FGF-1 141
Drug
Lead sponsor
Phage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Nov 10, 2026, 7:16 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes

NCT01080157
View directory record Official record
Conditions
Diabetes
Interventions
SCOUT DS measurement
Device
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
12
States / cities
Huntsville, Alabama • San Diego, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Nov 10, 2026, 7:16 PM EST
Recruiting Phase 4 Interventional

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

NCT04081701
View directory record Official record
Conditions
CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma, Medulloblastoma, Paraganglioma, Pituitary Adenoma
Interventions
Ga68-DOTATATE-PET/MRI
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 10, 2026, 7:16 PM EST
Terminated Phase 3 Interventional

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
pioglitazone, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
110
States / cities
Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Nov 10, 2026, 7:16 PM EST
Completed No phase listed Observational

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

NCT00945711
View directory record Official record
Conditions
Eating Disorder, Type 1 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Nov 10, 2026, 7:16 PM EST
Completed Not applicable Interventional Results available

Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study

NCT00884611
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Predictive Low Glucose Suspend Algorithm ON, Predictive Low Glucose Suspend Algorithm OFF
Device
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 46 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Nov 10, 2026, 7:16 PM EST
Not listed Not applicable Interventional

Evaluation of Medtronic DUO Extended Set

NCT04823312
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Experimental prospective single arm evaluating the Medtronic Duo Extended Set
Device
Lead sponsor
Atlanta Diabetes Associates
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Nov 10, 2026, 7:16 PM EST
Completed Phase 1 Interventional

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

NCT01398267
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar, lisinopril, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Chula Vista, California • Omaha, Nebraska • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 10, 2026, 7:16 PM EST
Completed Not applicable Interventional

Diabetic Shoulder Mobility

NCT02162212
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Optimized Shoulder Movement Program, ADA Guideline Instructed
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Nov 10, 2026, 7:16 PM EST
Completed Not applicable Interventional Results available

Trial Comparing 19 and 25-gauge EUS-FNA Needles

NCT01677312
View directory record Official record
Conditions
Cancer of Pancreas, Pancreatic Neoplasm
Interventions
Pancreatic Biopsy, Histological Samples
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Nov 10, 2026, 7:16 PM EST
Completed Not applicable Interventional

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

NCT00098800
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
fenretinide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Nov 10, 2026, 7:16 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 10, 2026, 7:16 PM EST
Completed Phase 1 Interventional

Continued Access to RXDX-105

NCT03784378
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
Interventions
RXDX-105
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 10, 2026, 7:16 PM EST
Completed Phase 4 Interventional Results available

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

NCT01562678
View directory record Official record
Conditions
Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Nov 10, 2026, 7:16 PM EST
Completed Not applicable Interventional

Genetic Counseling for Breast Cancer Survivors (GC for BC)

NCT02451735
View directory record Official record
Conditions
Breast Cancer
Interventions
Video and Booklet, Factsheet
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Nov 10, 2026, 7:16 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Long-Term Follow-Up of Survivors of Pediatric Cushing Disease

NCT03831958
View directory record Official record
Conditions
Cushing Disease
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 90 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 10, 2026, 7:16 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

NCT03860558
View directory record Official record
Conditions
Overweight, Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Lifestyle Intervention, No Intervention
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 10, 2026, 7:16 PM EST
Completed Phase 1 Interventional

Human Placental-Derived Stem Cell Transplantation

NCT01586455
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Adrenoleukodystrophy, Niemann-Pick Disease, Metachromatic Leukodystrophy, Wolman Disease, Krabbe's Disease, Gaucher's Disease, Fucosidosis, Batten Disease, Severe Aplastic Anemia, Diamond-Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Interventions
Human Placental Derived Stem Cell
Drug
Lead sponsor
New York Medical College
Other
Eligibility
0 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Valhalla, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Nov 10, 2026, 7:16 PM EST
Completed Phase 2 Interventional Results available

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

NCT00383149
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ixabepilone, Cetuximab
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Nov 10, 2026, 7:16 PM EST